Participants will receive subcutaneous (SC) injection of BIIB017 (peginterferon beta-1a) 63 microgram (μg) on Day 1, followed by 94 μg at Week 2, followed by 125 μg at Week 4, and then 125 μg SC injection every 2 weeks up to Week 96 in Part 1 of the study. Eligible participants who enter optional Part 2 of the study will receive 125 μg SC injections of BIIB017 every 2 weeks for 96 Weeks.

Administered as specified in the treatment arm

BIIB017 (peginterferon beta-1a)

Participants will receive Avonex (interferon beta type 1a) starting at a dose of 7.5 μg on Day 1, followed by an increase of 7.5 μg each week for 3 weeks, followed by 30 μg intramuscular (IM) injections every week up to Week 96 in Part 1 of the study. Eligible participants who enter optional Part 2 of the study will receive 125 μg SC injections of BIIB017 every 2 weeks for 96 Weeks.

Interferon beta type 1a

Patients receive perflutren protein-type A microspheres IV over 10 minutes and undergo CEUS over 60 minutes at 1-6 hours and at approximately 7 and 14 days after yttrium Y-90 radioembolization.

Undergo standard of care Y-90 radioembolization

Yttrium-90 Microsphere Radioembolization

Perflutren Protein-Type A Microspheres

Dynamic Contrast-Enhanced Ultrasound Imaging

Patients undergo standard of care yttrium Y-90 radioembolization.

BIIB017(페긴터페론 베타-1a), 인터페론 베타 1a형

이트륨-90 미세구체 방사선색전술, 퍼플루트렌 단백질 A형 미세구체, 동적 조영 증강 초음파 영상